25577-04-2 Usage
Uses
Used in Pharmaceutical Industry:
1,6,7-Trihydroxyxanthone is used as a potential anticancer agent for its ability to inhibit the growth of cancer cells and induce apoptosis. It is particularly promising in the development of drugs targeting various types of cancer due to its multifaceted therapeutic properties.
Used in Nutraceutical and Cosmeceutical Industries:
1,6,7-Trihydroxyxanthone is used as an antioxidant and anti-inflammatory agent for its potential to treat various diseases and conditions related to oxidative stress and inflammation. Its presence in dietary supplements and skincare products can contribute to overall health and wellness by combating free radicals and reducing inflammation.
Used in Research and Development:
1,6,7-Trihydroxyxanthone is utilized in scientific research to further investigate its pharmacological properties, mechanisms of action, and potential medical applications. This research is crucial for understanding the compound's full therapeutic potential and for developing new drugs and treatments based on its unique properties.
Check Digit Verification of cas no
The CAS Registry Mumber 25577-04-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,5,5,7 and 7 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 25577-04:
(7*2)+(6*5)+(5*5)+(4*7)+(3*7)+(2*0)+(1*4)=122
122 % 10 = 2
So 25577-04-2 is a valid CAS Registry Number.
25577-04-2Relevant academic research and scientific papers
Synthesis of xanthone derivatives and studies on the inhibition against cancer cells growth and synergistic combinations of them
Liu, Jie,Zhang, Jianrun,Wang, Huailing,Liu, Zhijun,Zhang, Cao,Jiang, Zhenlei,Chen, Heru
, p. 50 - 61 (2017/04/06)
34 Xanthones were synthesized by microwave assisted technique. Their in?vitro inhibition activities against five cell lines growth were evaluated. The SAR has been thoroughly discussed. 7-Bromo-1,3-dihydroxy-9H-xanthen-9-one (3-1) was confirmed as the most active agent against MDA-MB-231?cell line growth with an IC50 of 0.46?±?0.03?μM. Combination of 3-1 and 5,6-dimethylxanthone-4-acetic acid (DMXAA) showed the best synergistic effect. Apoptosis analysis indicated different contributions of early/late apoptosis and necrosis to cell death for both monomers and the combination. Western Blot implied that the combination regulated p53/MDM2 to a better healthy state. Furthermore, 3-1 and DMXAA arrested more cells on G2/M phase; while the combination arrested more cells on S phase. All the evidences support that the 3-1/DMXAA combination is a better anti-cancer therapy.
